Levels of Calcium, Corrected Calcium, Alkaline Phosphatase and Inorganic Phosphorus in Patients’ Serum with β-Thalassemia Major on Subcutaneous Deferoxamine

Muhammad Saboor*, Fatima Qudsia, Khansa Qamar and Moinuddin Moinuddin
Baqai Institute of Hematology, Baqai Medical University, Karachi, Pakistan

Abstract

Introduction: Combination of transfusion and chelation therapy has dramatically extended the life expectancy of patients with β-thalassemia major. Aim of this study was to determine of serum calcium, albumin corrected calcium, alkaline phosphatase and inorganic phosphorus in patients with β-thalassemia major on deferoxamine therapy.

Method: Sixty five patients with β-thalassemia major receiving blood transfusion with subcutaneous iron chelation therapy and 45 controls i.e. healthy individuals of the same age were enrolled in this study. Serum calcium, albumin corrected serum calcium, alkaline phosphatase and inorganic phosphorus levels were determined in all individuals.

Result: In patients with β-thalassemia major serum calcium and albumin corrected serum calcium levels were low as compared with controls (p<0.01 and <0.04 respectively). All patients had high alkaline phosphatase level than in controls (p<0.001). Levels of inorganic phosphorus were also high in patients than controls (p<0.01). Serum albumin did not show any statistically significant difference between patients and normal subjects (p>0.11).

Conclusion: It is concluded that bone health is greatly compromised in patients with β-thalassemia major and bone related biochemical abnormalities i.e. hypocalcaemia, hyperphosphatemia and hyperphosphatasia are common in thalassemia major patients.

Keywords: β-Thalassemia major; Calcium; Albumin; Corrected calcium; Alkaline phosphatase; Inorganic phosphorus

Introduction

Prevalence of β-thalassemia is high amongst the genetic disorders of hemoglobin synthesis. Frequency of β-thalassemia trait is about 5-6% in Pakistan. β-thalassemia major is characterized by severe hemolytic anemia that requires regular blood transfusion. Life expectancy of these patients is strikingly prolonged with repeated blood transfusion and iron chelation therapy but complications associated with secondary hemochromatosis are still a challenge [1,2]. A series of complications including osteopenia, osteoporosis, scoliosis, spinal deformities, nerve compression and spontaneous fractures are frequently seen in transfusion dependent thalassemics [3].

Deferoxamine is a trihydroxamic acid produced by Streptomyces pilosus [4]. It is being used as iron chelator for over three decades [5]. Regular blood transfusion along with deferoxamine infusions has improved the management of patients with β-thalassemia major [6]. However, iron chelation has its own adverse effects on thalassemics [7].

Calcium, inorganic phosphorus and alkaline phosphate are the essential bio materials of human bones and teeth [8]. Hydroxyapatite is the mineral form of calcium and phosphorous that provides rigidity to osseous skeleton. Alkaline phosphate assists in the deposition of the hydroxyapatite crystals between the collagen fibrils of bone [9]. Calcium is the 5th most plentiful element in human body playing a major role in skeletal mineralization [10]. Serum calcium is found in free as well as in bound form with proteins especially albumin. Adjustment of serum total calcium concentration (corrected calcium) for albumin is essential for the diagnosis of hypo and hypocalcaemia [11]. Phosphorous has paramount effect in conjunction with calcium on development of bones [12]. Osseous tissue contains 85% of total body phosphorous. Alkaline phosphatase is responsible for promoting bone mineralization by increasing the local concentration of inorganic phosphorus [8].

Bone turnover is evaluated with various specific and sensitive serological markers. Serum calcium, phosphorous and alkaline phosphatase are characteristically altered with bone impairment in patients with thalassemia [3]. This study was conducted to evaluate the levels of calcium, albumin corrected calcium, alkaline phosphatase and inorganic phosphorus in patients with β-thalassemia major on deferoxamine infusion. In Pakistan no study has been conducted for the evaluation of these biochemical markers in patients with transfusion dependent β-thalassemia who are on deferoxamine therapy.

Method

The study was approved by ethical committee of Baqai medical university Karachi, Pakistan. Written informed consent was obtained from the parents of the patients and controls enrolled in this study. Sixty-five patients with β-thalassemia major and 45 healthy individuals (controls) aged between 15 to 25 years were recruited in this study. Venous blood samples were collected in un-anticoagulated tubes and allowed to clot. Serum was separated and analyzed within 6 hours. Serum calcium was determined by colorimetric method using methylmol blue indicator while serum phosphorus level was determined by ammonium molybdate end point method. Alkaline phosphatase was also measured by colorimetric method using p-nitrophenyl phosphate. Serum albumin was determined by colorimetric method using bromocresol green method in semi auto analyzer.

*Corresponding author: Muhammad Saboor, Baqai Institute of Hematology, Baqai Medical University, Karachi, Pakistan. Tel: 0333-2279927; E-mail: msaboor81@gmail.com

Received November 26, 2013; Accepted January 24, 2014; Published January 27, 2014


Copyright: © 2014 Samos M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Table 1: Levels of serum calcium, corrected calcium, alkaline phosphatase and inorganic phosphorus in patients with β-thalassemia major and controls.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Controls</th>
<th>Thalassemics</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium (mg/dl)</td>
<td>9.5 ± 0.6</td>
<td>8.9 ± 0.47</td>
<td>0.01</td>
</tr>
<tr>
<td>Corrected calcium (mg/dl)</td>
<td>9.26 ± 0.54</td>
<td>8.83 ± 0.58</td>
<td>0.04</td>
</tr>
<tr>
<td>Alkaline phosphatase (IU/l)</td>
<td>124 ± 51.81</td>
<td>368 ± 176.36</td>
<td>0.001</td>
</tr>
<tr>
<td>Inorganic phosphorus (mg/dl)</td>
<td>3.42 ± 0.65</td>
<td>3.75 ± 0.26</td>
<td>0.01</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>4.35 ± 0.46</td>
<td>4.08 ± 0.46</td>
<td>0.11</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SD

Discussion

β-thalassemia major is an inherited, autosomal recessive hemoglobinopathy that results in a large number of hematological, biochemical and systemic abnormalities. Results of this study showed decreased level of serum calcium and corrected serum calcium and high levels of inorganic phosphorus in patients with β-thalassemia major as compared with controls (p<0.01 and <0.04 respectively). Alkaline phosphatase and inorganic phosphorus were significantly higher in thalassemic group than controls (p<0.001 and <0.01 respectively). Statistically no significant difference was observed for level of albumin among the patients and controls as shown in Table 1.

Bone changes are frequently seen in patients with β-thalassemia major. These complications increase with regular blood transfusion, secondary hemochromatosis, iron chelation therapy, erythropoietin hyperplasia and nutritional deficit [15,18]. A paradigm of deferoxamine induced toxicity is failure of linear growth, associated with evidence of cartilaginous dysplasia of the long bones and spine. Frequency of fractures are high in these patients even with only mild anemia and normal serum ferritin levels.

Well balanced nutrition, patient education, diet counseling and supplementation therapy of calcium and vitamin-D for high risk group of β-thalassemia is strongly recommended. Regular monitoring of serum calcium, alkaline phosphatase and inorganic phosphorus is also recommended. Proper monitoring of parathyroid hormone may also improve skeletal status in these patients.

References